RR-M01
/ Roc Rock Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 03, 2025
A clinical trial to evaluate the safety and preliminary efficacy results of CAR-macrophage in Metastatic HER2-Low Expressing and HER2-Positive Solid Tumors
(SITC 2025)
- P=N/A | "Further CAR-M investigations targeting additional antigens are currently being planned.Trial Registration ChiCTR2400082776 and ChiCTR2400080078Ethics Approval Approval Letter of Clinical Research Ethics Committee of The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. ID: XYFY2023-KL107-01 and XYFY2024-KL077-01"
Clinical • Metastases • Oncology • Solid Tumor • CSF2 • HER-2
1 to 1
Of
1
Go to page
1